TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20222036

Group type: EXPERIMENTAL
Intervention: Outcome-based education on rational prescribing
Number of subjects: 112

Group type: COMPARATOR
Intervention: Traditional CME program on rational prescribing
Number of subjects: 112
Study: 18662287

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg b.d.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 15807806

Group type: EXPERIMENTAL
Intervention: 96-well microplate-based colorimetric method for SC quantification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-Squame tape disks
Number of subjects: 0
Study: 12408206

Group type: EXPERIMENTAL
Intervention: Computer-based tailored print material intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary telecounseling intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined interventions (computer-based tailored print material + telecounseling)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Generic print materials (control group)
Number of subjects: 0
Study: 12109042

Group type: COMPARATOR
Intervention: Reference product (3 x 40 mg tablets)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test product A (3 x 40 mg tablets)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Test product B (1 x 120 mg tablet)
Number of subjects: 24
Study: 9613910

Group type: EXPERIMENTAL
Intervention: Lovastatin (20-40 mg daily)
Number of subjects: 6605
Study: 7710536

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 2711525

Group type: EXPERIMENTAL
Intervention: Redon high-vacuum drainage system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly developed, permanently closed drainage system with maximum obtainable low pressure of 80% vacuum
Number of subjects: 0
Study: 30510098

Group type: EXPERIMENTAL
Intervention: Epley manoeuvre
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sham manoeuvre
Number of subjects: 134
Study: 29031763

Group type: EXPERIMENTAL
Intervention: Sodium oxybate treatment in SXB-15
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Sodium oxybate treatment in SXB-22
Number of subjects: 437
Study: 25934164

Group type: EXPERIMENTAL
Intervention: LNG20 (52-mg levonorgestrel intrauterine contraceptive)
Number of subjects: 1751
Study: 23857972

Group type: EXPERIMENTAL
Intervention: Sunitinib plus capecitabine (2,000 mg/m2)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Capecitabine monotherapy (2,500 mg/m2)
Number of subjects: 442
Study: 22088587

Group type: EXPERIMENTAL
Intervention: Flavonoids of puerarin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Tanshinone II A sulfate
Number of subjects: 67
Study: 18990499

Group type: EXPERIMENTAL
Intervention: 5 mg hydrocortisone
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 30 mg hydrocortisone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 17143357

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.5 g/kg over 4 hours, every 12 hours for 3 doses
Number of subjects: 34

Group type: COMPARATOR
Intervention: Phototherapy alone
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 34
Study: 14673697

Group type: EXPERIMENTAL
Intervention: Transdermal absorption of estradiol in normal subjects
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Transdermal absorption of estradiol in patients with polyneuropathy
Number of subjects: 39
Study: 10871969

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin treatment at home
Number of subjects: 201

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin treatment in hospital
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Outpatient management
Number of subjects: 201
Study: 9663831

Group type: EXPERIMENTAL
Intervention: Lactulose 5 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psyllium 3.4 g
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylcellulose 2 g
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo 10 g
Number of subjects: 0
Study: 8200722

Group type: EXPERIMENTAL
Intervention: Seaprose (90 mg/day for 10 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30349279

Group type: EXPERIMENTAL
Intervention: FDC perindopril/amlodipine (5/5 mg, uptitrated to 10/10 mg every two weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FDC perindopril/amlodipine
Number of subjects: 60
Study: 27600155

Group type: EXPERIMENTAL
Intervention: SBRT to 66Gy in 3 fractions (one week)
Number of subjects: 102

Group type: COMPARATOR
Intervention: 3DCRT to 70Gy (7 weeks)
Number of subjects: 102
Study: 24834887

Group type: EXPERIMENTAL
Intervention: 500 mg/kg iodine load and 80 kV(p) tube voltage
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 400 mg/kg iodine load and 80 kV(p) tube voltage
Number of subjects: 136

Group type: COMPARATOR
Intervention: 600 mg/kg iodine load and 120 kV(p) tube voltage
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: All groups (400-80, 500-80, 600-120)
Number of subjects: 136
Study: 22491963

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 10
Study: 20634736

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage with leucine (22.5 mg/kg, total 45 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carbohydrate beverage without leucine (control)
Number of subjects: 20
Study: 18576898

Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg plus misoprostol 200 microg twice/day for 14 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Diclofenac 75 mg alone
Number of subjects: 19
Study: 16022753

Group type: EXPERIMENTAL
Intervention: Galactose (50 g)/guar gum (2.5 g) load with standard breakfast (GG)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Water (250 ml) with standard breakfast (W)
Number of subjects: 58
Study: 12450328

Group type: EXPERIMENTAL
Intervention: Controlled prior frequency of occurrence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Global memory model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word-frequency effects
Number of subjects: 0
Study: 10619535

Group type: EXPERIMENTAL
Intervention: Standard clinic treatment
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Oral premedication
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Relaxation-based procedures
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Anxiety intervention (general)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 381
Study: 8566676

Group type: EXPERIMENTAL
Intervention: Glucomannan 3 gr/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glucomannan 4 gr/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1826823

Group type: COMPARATOR
Intervention: Abrasio only
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Medroxy progesterone acetate 500 mg i.m. twice weekly for 3 months
Number of subjects: 292
Study: 7042372

Group type: EXPERIMENTAL
Intervention: Betamethasone 9 mg (Celeston Chronodose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31049826

Group type: EXPERIMENTAL
Intervention: d3RP‐NF2
Number of subjects: 45

Group type: COMPARATOR
Intervention: dHEP‐NF2
Number of subjects: 45
Study: 29952137

Group type: EXPERIMENTAL
Intervention: Inspiratory external resistance (2-20 cmH2 O/L/sec)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Expiratory external resistance (2-20 cmH2 O/L/sec)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined external resistance (2-20 cmH2 O/L/sec)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combined inspiratory and expiratory external resistance (2-20 cmH2 O/L/sec)
Number of subjects: 9
Study: 27802950

Group type: EXPERIMENTAL
Intervention: Family Navigator (FN) intervention with daily contact addressing informational and emotional communication needs.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Family Navigator (FN) intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 24332392

Group type: EXPERIMENTAL
Intervention: Unplugged curriculum
Number of subjects: 7079

Group type: COMPARATOR
Intervention: Usual health education (control)
Number of subjects: 7079
Study: 22145671

Group type: COMPARATOR
Intervention: MOVE programme
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Methylphenidate plus MOVE programme
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard nutrition counselling
Number of subjects: 101
Study: 19149817

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17189801

Group type: EXPERIMENTAL
Intervention: Tetracaine hydrochloride 0.5% (TetraVisc)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lidocaine 2% jelly
Number of subjects: 100
Study: 15159498

Group type: EXPERIMENTAL
Intervention: High-cholesterol subgroup (no-APOE epsilon4 allele)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Normal-cholesterol subgroups (with or without APOE epsilon4)
Number of subjects: 443
Study: 12352474

Group type: EXPERIMENTAL
Intervention: Erythromycin (ERY)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 68
Study: 9843526

Group type: EXPERIMENTAL
Intervention: Torso heating (THT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control condition (CT) with Arctic mitts
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control condition (CT)
Number of subjects: 6
Study: 7865319

Group type: EXPERIMENTAL
Intervention: Computerized Risk Assessment Battery (C-RAB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper-and-pencil version of Risk Assessment Battery (RAB)
Number of subjects: 0
Study: 2912011

Group type: EXPERIMENTAL
Intervention: Coffee at 58 degrees C (steaming hot)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coffee at 37 degrees C (warm)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coffee at 4 degrees C (ice cold)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All temperatures of coffee (hot, warm, cold)
Number of subjects: 0
Study: 5531862

Group type: EXPERIMENTAL
Intervention: Oral alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral alcohol in a patient with a completely denervated hand
Number of subjects: 0
Study: 31416745

Group type: EXPERIMENTAL
Intervention: High dose minocycline (200 mg/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low dose minocycline (100 mg/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 29259181

Group type: EXPERIMENTAL
Intervention: Omega-3 capsules (2 g/day for 8 weeks)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Fresh fish (250 g twice weekly for 8 weeks)
Number of subjects: 106
Study: 25780304

Group type: EXPERIMENTAL
Intervention: PEG‐Asc (2‐L polyethylene glycol with ascorbic acid 20 g)
Number of subjects: 226

Group type: COMPARATOR
Intervention: 4‐L PEG
Number of subjects: 226
Study: 24792591

Group type: EXPERIMENTAL
Intervention: 30 ml iodinated contrast agent/100 kVp
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 30 ml iodinated contrast agent/80 kVp
Number of subjects: 120

Group type: COMPARATOR
Intervention: 70 ml iodinated contrast agent/120 kVp
Number of subjects: 120
Study: 22632135

Group type: EXPERIMENTAL
Intervention: Psycho-educational program for caregivers (10 sessions of 90 minutes over 5 weeks) + antipsychotic drug treatment for patients
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no psycho-educational program)
Number of subjects: 70
Study: 19253021

Group type: EXPERIMENTAL
Intervention: Maitake liquid extract at 0.1, 0.5, 1.5, 3, or 5 mg/kg twice daily for 3 weeks
Number of subjects: 34
Study: 17312364

Group type: EXPERIMENTAL
Intervention: Skin protection ointment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Skin care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protective gloves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Skin protection
Number of subjects: 0

Group type: COMPARATOR
Intervention: UV hardening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 16061595

Group type: EXPERIMENTAL
Intervention: Donor Milk (DM)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Preterm Formula (PF)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Mother's Milk (MM)
Number of subjects: 243
Study: 12234565

Group type: EXPERIMENTAL
Intervention: High-dose LMWH for thromboprophylaxis for the first postoperative week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged thromboprophylaxis with dalteparin or enoxaparin for a further 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis with LMWH for at least one month
Number of subjects: 0
Study: 10212537

Group type: EXPERIMENTAL
Intervention: Immediate or delayed-immediate implant placement techniques
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Short implants in the posterior region of the maxilla
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Clinical parameters (bleeding, pocket depth, implant mobility)
Number of subjects: 143
Study: 7530641

Group type: EXPERIMENTAL
Intervention: Real feedback (R-FB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dummy feedback (D-FB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Perceptuomotor feedback (PM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Complex task difficulty
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Simple task difficulty
Number of subjects: 10
Study: 2212968

Group type: EXPERIMENTAL
Intervention: Finger blood pressure monitor (Marshall, Astro F‐88)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Brachial mercury sphygmomanometer
Number of subjects: 125
Study: 508702

Group type: EXPERIMENTAL
Intervention: Intramuscular Fe dextran, 100 mg twice per week for 10-12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral Fe, 120 mg/d, 6 d/week for 10-12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous Fe by total dose infusion of Fe dextran
Number of subjects: 0
Study: 30256915

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 4,000 IU/d
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation 2,000 IU/d
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentrations
Number of subjects: 70
Study: 29121356

Group type: EXPERIMENTAL
Intervention: Subconjunctival injection of 0.5 mL cefazolin-lidocaine solution (0.3 mL cefazolin and 0.2 mL 2% lidocaine)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Subconjunctival injection of 0.5 mL cefazolin-balanced salt solution (0.3 mL cefazolin and 0.2 mL balanced salt solution)
Number of subjects: 54
Study: 26384727

Group type: EXPERIMENTAL
Intervention: Nurse-led care (active monitoring)
Number of subjects: 42
Study: 23714599

Group type: EXPERIMENTAL
Intervention: High-resistance-moderate-endurance (Re)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moderate-resistance-high-endurance (rE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moderate-resistance-moderate-endurance (re)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 100
Study: 21791109

Group type: EXPERIMENTAL
Intervention: Multimodal supportive care intervention 'Living with Prostate Cancer' combining self-management with tele-based group peer support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodal supportive care intervention 'Living with Prostate Cancer'
Number of subjects: 0
Study: 19185342

Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 25928

Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 25928

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 25928

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 25928

Group type: COMPARATOR
Intervention: Reboxetine
Number of subjects: 25928
Study: 16461038

Group type: EXPERIMENTAL
Intervention: Bezafibrate therapy
Number of subjects: 3026

Group type: EXPERIMENTAL
Intervention: Change in HDL cholesterol (continuous variable)
Number of subjects: 3026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3026
Study: 15265759

Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin (BH(4))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 32
Study: 10065696

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 400 microg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol 400 microg plus oral activated charcoal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled placebo plus oral activated charcoal
Number of subjects: 12
Study: 7733034

Group type: EXPERIMENTAL
Intervention: Plant-protein diet with vitamin B-6 intakes of 0.5, 1.0, 1.5, and 2.0 mg/d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Animal-protein diet with vitamin B-6 intakes of 0.5, 1.0, 1.5, and 2.0 mg/d
Number of subjects: 8
Study: 2394068

Group type: EXPERIMENTAL
Intervention: Arm vein infusion technique
Number of subjects: 46

Group type: COMPARATOR
Intervention: Femoral vein infusion with single location dynamic scanning
Number of subjects: 46
Study: 6153834

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 7
Study: 31377905

Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF injection (bevacizumab 1.25 mg or ranibizumab 0.5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexamethasone implant (0.7 mg)
Number of subjects: 40
Study: 31111752

Group type: EXPERIMENTAL
Intervention: Shengji Yuhong ointment
Number of subjects: 400
Study: 28632557

Group type: EXPERIMENTAL
Intervention: End-plate perforation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no end-plate perforation)
Number of subjects: 30
Study: 25336921

Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg) + Valsartan (160 mg)
Number of subjects: 54
Study: 22631077

Group type: EXPERIMENTAL
Intervention: Surgical atrial incision aimed at decreasing the incidence of intraatrial reentrant tachycardia (IART)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no surgical atrial incision)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Surgical atrial incision
Number of subjects: 29
Study: 20448359

Group type: EXPERIMENTAL
Intervention: Combination of salvia miltiorrhiza and prednisolone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Prednisolone alone
Number of subjects: 120
Study: 17505680

Group type: COMPARATOR
Intervention: Nissen fundoplication (NF)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vertical gastric plication (VGP)
Number of subjects: 14
Study: 15661417

Group type: EXPERIMENTAL
Intervention: Tadalafil (TAD) 20 mg on alternate days for 4 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PLB) for 4 weeks
Number of subjects: 32
Study: 12033092

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8%
Number of subjects: 35

Group type: COMPARATOR
Intervention: Propofol 3 mg.kg‐1 and fentanyl 2 micrograms.kg‐1
Number of subjects: 35
Study: 10087242

Group type: EXPERIMENTAL
Intervention: Prempak C 0.625(R) hormone replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study: 8649914

Group type: EXPERIMENTAL
Intervention: Nebulised budesonide (2 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexamethasone syrup (0.6 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 2315072

Group type: EXPERIMENTAL
Intervention: Bottle feeding avoided in Weeks 2-6 postpartum
Number of subjects: 128

Group type: COMPARATOR
Intervention: Approximately one bottle per day given during Weeks 2-6 postpartum
Number of subjects: 128
Study: 7018726

Group type: EXPERIMENTAL
Intervention: MER (methanol extraction residue BCG) immunotherapy during chemotherapy
Number of subjects: 167

Group type: COMPARATOR
Intervention: Combination chemotherapy (CVPP or BAVS or alternating cycles of CVPP and BAVS)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: MER for patients with at least one pretreatment positive skin test
Number of subjects: 167
Study: 31733004

Group type: EXPERIMENTAL
Intervention: Yeast culture (YC) fermented for 12, 24, 36, 48 or 60 hr
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Yeast culture (YC) fermented for 24 hr
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Yeast culture (YC) fermented for 60 hr
Number of subjects: 350

Group type: COMPARATOR
Intervention: Basal diet without YC supplementation
Number of subjects: 350

Group type: COMPARATOR
Intervention: Commercial YC product (SZ2)
Number of subjects: 350
Study: 31084533

Group type: EXPERIMENTAL
Intervention: IDS-1L with one layer of adhesive
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IDS-2L with two layers of adhesive
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IDS-F with one layer of adhesive and one layer of flowable RBC
Number of subjects: 48

Group type: COMPARATOR
Intervention: DDS (delayed dentin sealing) with no layer of adhesive (control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SC-P with pumice rubbing
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SC-PC with pumice rubbing followed by tribochemical silica coating
Number of subjects: 48
Study: 29084522

Group type: EXPERIMENTAL
Intervention: Vitamin D3 10,000 IU daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23637005

Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin (rhTPO)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 25012990

Group type: EXPERIMENTAL
Intervention: Lixisenatide before breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lixisenatide before main meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0